menu

Is the ‘Weight’ Over? Next Generation of Anti-Obesity Therapeutics

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Is the ‘Weight’ Over? Next Generation of Anti-Obesity Therapeutics

0.50 credits
.5
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Obesity affects 600 million people globally and over one third of the American population. Along with associated comorbidities, including cardiovascular disease, stroke, diabetes, and cancer; the direct and indirect costs of managing obesity are 21% of the total medical costs. The elevated risk for severe disease and death from COVID-19 associated with obesity and its comorbidities underscores the urgency to develop and implement effective prevention and treatment strategies.  Current strategies for treating obesity rely on a "one-size-fits-all" approach despite significant pathophysiological heterogeneity among people with obesity. As a result, the response to obesity pharmacotherapy as well as diet and lifestyle interventions continues to be a hit-or-miss phenomenon with highly variable efficacies and outcomes. Currently available drugs only offer a 5% weight loss (in comparison to placebo) if both drug and placebo are given with a lifestyle intervention. However, we are now seeing the emergence of second-generation medications. Knowledge of the safety and efficacy of newly available therapeutic options is vital to health care practitioners as they work with patients to develop optimal, individualized, and long-term strategies for overcoming obesity.

  • Disclosure of Conflicts of Interest

    According to the disclosure policy of the University of Cincinnati College of Medicine, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with the commercial companies related to this activity. All relevant relationships that are identified are reviewed for potential conflicts of interest. If a conflict of interest is identified, it is the responsibility of the University of Cincinnati College of Medicine to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

    Disclaimer Statement
    The opinions expressed during the endured activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati or CORE Medical Education. The information is presented for the purpose of advancing the attendees’ professional development.

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Neither the University of Cincinnati nor CORE Medical Education, LLC, recommends the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    The following faculty has reported relationships with ineligible companies that have been mitigated:

    Robert F. Kushner, MD, has disclosed the following relevant financial relationships:
    Director, officer, partner, employee, advisor/consultant, or trustee for: Novo Nordisk; WW; Lilly; Pfizer

    John J. Russell, MD (host) has disclosed the following relevant financial relationships:
    Speaker and Advisory Board Member: GlaxoSmithKline, US Sanofi, Bayer, Pfizer

    The following reviewers/planners/authors have reported no relationships with ineligible companies:

    • Susan Tyler, PhD, CMP, CHCP, CCPD/CME Associate Dean, has nothing to disclose.
    • Robert Ellis, MD, CME Reviewer, has nothing to disclose.
    • Heather Muskopf, Program Manager, has nothing to disclose.
    • Amy Spegal, Program Coordinator, has nothing to disclose.
    • Otto Ratz, MD, has nothing to disclose.
    • Christina Culbert, MSc, has nothing to disclose.
  • Target Audience

    The intended audience for this activity are physicians and other health care professionals involved in the management of patients with obesity.

  • Learning Objectives

    • Discuss strategies/tools to screen and diagnose, and review barriers for discussion of weight during visits;
    • Distinguish and identify newly available and emerging therapeutic approaches to obesity;
    • Incorporate obesity counseling as a tool for patient education and engagement in weight management.
  • Accreditation and Credit Designation Statements

    Accreditation Statement
    This CME activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and CORE Medical Education, LLC. University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

    Credit Designation
    University of Cincinnati designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    This CME activity was developed through the joint providership of the University of Cincinnati and CORE Medical Education, LLC.

  • Commercial Support

    This CME activity is supported by an educational grant from Novo Nordisk Inc.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Obesity affects 600 million people globally and over one third of the American population. Along with associated comorbidities, including cardiovascular disease, stroke, diabetes, and cancer; the direct and indirect costs of managing obesity are 21% of the total medical costs. The elevated risk for severe disease and death from COVID-19 associated with obesity and its comorbidities underscores the urgency to develop and implement effective prevention and treatment strategies.  Current strategies for treating obesity rely on a "one-size-fits-all" approach despite significant pathophysiological heterogeneity among people with obesity. As a result, the response to obesity pharmacotherapy as well as diet and lifestyle interventions continues to be a hit-or-miss phenomenon with highly variable efficacies and outcomes. Currently available drugs only offer a 5% weight loss (in comparison to placebo) if both drug and placebo are given with a lifestyle intervention. However, we are now seeing the emergence of second-generation medications. Knowledge of the safety and efficacy of newly available therapeutic options is vital to health care practitioners as they work with patients to develop optimal, individualized, and long-term strategies for overcoming obesity.

  • Disclosure of Conflicts of Interest

    According to the disclosure policy of the University of Cincinnati College of Medicine, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with the commercial companies related to this activity. All relevant relationships that are identified are reviewed for potential conflicts of interest. If a conflict of interest is identified, it is the responsibility of the University of Cincinnati College of Medicine to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

    Disclaimer Statement
    The opinions expressed during the endured activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati or CORE Medical Education. The information is presented for the purpose of advancing the attendees’ professional development.

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Neither the University of Cincinnati nor CORE Medical Education, LLC, recommends the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    The following faculty has reported relationships with ineligible companies that have been mitigated:

    Robert F. Kushner, MD, has disclosed the following relevant financial relationships:
    Director, officer, partner, employee, advisor/consultant, or trustee for: Novo Nordisk; WW; Lilly; Pfizer

    John J. Russell, MD (host) has disclosed the following relevant financial relationships:
    Speaker and Advisory Board Member: GlaxoSmithKline, US Sanofi, Bayer, Pfizer

    The following reviewers/planners/authors have reported no relationships with ineligible companies:

    • Susan Tyler, PhD, CMP, CHCP, CCPD/CME Associate Dean, has nothing to disclose.
    • Robert Ellis, MD, CME Reviewer, has nothing to disclose.
    • Heather Muskopf, Program Manager, has nothing to disclose.
    • Amy Spegal, Program Coordinator, has nothing to disclose.
    • Otto Ratz, MD, has nothing to disclose.
    • Christina Culbert, MSc, has nothing to disclose.
  • Target Audience

    The intended audience for this activity are physicians and other health care professionals involved in the management of patients with obesity.

  • Learning Objectives

    • Discuss strategies/tools to screen and diagnose, and review barriers for discussion of weight during visits;
    • Distinguish and identify newly available and emerging therapeutic approaches to obesity;
    • Incorporate obesity counseling as a tool for patient education and engagement in weight management.
  • Accreditation and Credit Designation Statements

    Accreditation Statement
    This CME activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and CORE Medical Education, LLC. University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

    Credit Designation
    University of Cincinnati designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    This CME activity was developed through the joint providership of the University of Cincinnati and CORE Medical Education, LLC.

  • Commercial Support

    This CME activity is supported by an educational grant from Novo Nordisk Inc.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule1 Oct 2023